The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden administration that would have allowed Medicare and Medicaid ...

The previous administration attempted to have Medicare Part D and Medicaid cover anti-obesity drugs under the Contract Year 2026 MA and Part D rule, which would have substantially increased access ...

The Centers for Medicare and Medicaid Services did ... in a statement that it may consider future policy options for anti-obesity medications “pending further review of both the potential ...

High-demand obesity treatments will not be covered under the federal government’s Medicare program, it was announced Friday. The Centers for Medicare and Medicaid Services said late Friday that ...

The bad news is that Medicaid does not cover anti-obesity medications in New York, putting life-changing treatment out of reach for those who need it most. Fourteen states and counting have begun ...

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But access remains limited.

The AMA passed a resolution to increase access to anti-obesity medications at its annual House of Delegates meeting.The resolution was championed by the Endocrine Society, according to a press release ...

As a physician assistant in Charlotte, I have witnessed firsthand the transformative impact of new obesity medications on ...

The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate.

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path ...